Newleos emerges with $93.5 million and CNS drugs licensed from Roche

Boston, USA-based Newleos Therapeutics, a neuroscience company co-founded by Longwood Fund and seasoned leaders in CNS drug development, has announced its emergence and the closing of an oversubscribed $93.5 million Series A financing.

Newleos’ clinical-stage pipeline was in-licensed from Swiss pharma giant Roche (ROG: SIX) and includes multiple oral small molecules targeting novel mechanisms across a broad range of indications including generalized anxiety, social anxiety, substance use disorders and cognitive impairment.

David Donabedian, founding chief executive, Newleos and executive partner, Longwood Fund, said: “Anxiety and substance use disorders represent some of the most prevalent neuropsychiatric indications with high unmet need, representing more than 25% of mental illnesses in US adults and impacting over 60 million individuals.